Updated:
Zenas BioPharma
Zenas BioPharma is an asset manager based in Waltham; the Altss profile covers its classification, headquarters, registration, AUM band, and key contacts for...
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Waltham
Corporate office
852 Winter Street Suite 250, Waltham, MA 02451, United States
Principals
Lonnie Moulder
Chief Executive Officer and Chairman of the Board of Directors
Sector focus
Frequently asked questions
Who makes investment decisions at Zenas BioPharma?
Lonnie Moulder serves as CEO and Chairman, leading corporate strategy and development. The board includes executives such as Patricia Allen, James Boylan, Patrick Enright, Hongbo Lu, Jake Nunn, and John Orloff. (per firm website)
What is Zenas BioPharma's primary therapeutic focus?
The firm concentrates exclusively on autoimmune diseases with significant unmet medical need. Its two lead candidates target B-cell activity and BTK pathways to address multiple indications. (per firm website)
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Source record modified: . Public records carry source-specific dates where available. No population-wide measured refresh cadence or universal verification deadline is established here. Page modified, source captured, fact observed, entity verified and aggregate measured describe different events. Check the date attached to the relevant claim; a missing verification date means unknown. Stored source history does not establish a customer-facing historical-analysis interface. To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: